163 related articles for article (PubMed ID: 36372832)
21. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Van Swearingen AED; Siegel MB; Deal AM; Sambade MJ; Hoyle A; Hayes DN; Jo H; Little P; Dees EC; Muss H; Jolly T; Zagar TM; Patel N; Miller CR; Parker JS; Smith JK; Fisher J; Shah N; Nabell L; Nanda R; Dillon P; Abramson V; Carey LA; Anders CK
Breast Cancer Res Treat; 2018 Oct; 171(3):637-648. PubMed ID: 29938395
[TBL] [Abstract][Full Text] [Related]
22. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.
Paulson AK; Linklater ES; Berghuis BD; App CA; Oostendorp LD; Paulson JE; Pettinga JE; Melnik MK; Vande Woude GF; Graveel CR
Mol Cancer Res; 2013 Sep; 11(9):1112-21. PubMed ID: 23825050
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
Rao PS; Labhart M; Mayhew SL; Thirumala S; Rao US
Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
[TBL] [Abstract][Full Text] [Related]
24. Patients undergoing surgery of intracranial metastases have different outcomes based on their primary pathology.
Chaichana KL; Gadkaree S; Rao K; Link T; Rigamonti D; Purtell M; Browner I; Weingart J; Olivi A; Gallia G; Bettegowda C; Brem H; Lim M; Quinones-Hinojosa A
Neurol Res; 2013 Dec; 35(10):1059-69. PubMed ID: 24070329
[TBL] [Abstract][Full Text] [Related]
25. Real-world association of HER2/
Stein SM; Snider J; Ali SM; Miksad RA; Alexander BM; Castellanos E; Schrock AB; Madison R; Swaminathan A; Venstrom JM; McCusker M
Future Oncol; 2021 Nov; 17(31):4101-4114. PubMed ID: 34463133
[TBL] [Abstract][Full Text] [Related]
26. HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.
Fusco N; Bosari S
World J Gastroenterol; 2016 Sep; 22(35):7926-37. PubMed ID: 27672288
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
28. Emergence of
Subramanian J; Katta A; Masood A; Vudem DR; Kancha RK
Oncologist; 2019 Dec; 24(12):e1303-e1314. PubMed ID: 31292270
[TBL] [Abstract][Full Text] [Related]
29. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
Mittendorf EA; Vila J; Tucker SL; Chavez-MacGregor M; Smith BD; Symmans WF; Sahin AA; Hortobagyi GN; Hunt KK
JAMA Oncol; 2016 Jul; 2(7):929-36. PubMed ID: 26986538
[TBL] [Abstract][Full Text] [Related]
30. Cell lineage tracing links ERα loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype.
Ding Y; Liu Y; Lee DK; Tong Z; Yu X; Li Y; Xu Y; Lanz RB; O'Malley BW; Xu J
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006643
[TBL] [Abstract][Full Text] [Related]
31. The Impact of Targeted Therapy on Intracranial Metastatic Disease Incidence and Survival.
Erickson AW; Das S
Front Oncol; 2019; 9():797. PubMed ID: 31508362
[TBL] [Abstract][Full Text] [Related]
32. Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies.
Takahashi N; Iwasa S; Taniguchi H; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita N; Kato K; Hamaguchi T; Shimada Y; Yamada Y
Br J Cancer; 2016 Apr; 114(9):1003-11. PubMed ID: 27002940
[TBL] [Abstract][Full Text] [Related]
33. Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well to Moderately Differentiated Carcinoma.
Liao JB; Lee HP; Fu HT; Lee HS
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):374-382. PubMed ID: 27753660
[TBL] [Abstract][Full Text] [Related]
34. Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer.
Zhang EY; Cristofanilli M; Robertson F; Reuben JM; Mu Z; Beavis RC; Im H; Snyder M; Hofree M; Ideker T; Omenn GS; Fanayan S; Jeong SK; Paik YK; Zhang AF; Wu SL; Hancock WS
J Proteome Res; 2013 Jun; 12(6):2805-17. PubMed ID: 23647160
[TBL] [Abstract][Full Text] [Related]
35. Expression of Four Autophagy-Related Genes Accurately Predicts the Prognosis of Gastrointestinal Cancer in Asian Patients.
Tang H; Liang Y; Xu S; Xia R; Shen J; Zhang Y; Gong X; Min Y; Zhang D; Zhao T; Wang S; Zhang Y; Wang C
Dis Markers; 2021; 2021():7253633. PubMed ID: 34484469
[TBL] [Abstract][Full Text] [Related]
36. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.
Lam PB; Burga LN; Wu BP; Hofstatter EW; Lu KP; Wulf GM
Mol Cancer; 2008 Dec; 7():91. PubMed ID: 19077306
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.
Tajiri R; Ooi A; Fujimura T; Dobashi Y; Oyama T; Nakamura R; Ikeda H
Hum Pathol; 2014 Apr; 45(4):725-34. PubMed ID: 24491355
[TBL] [Abstract][Full Text] [Related]
38. Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis.
Erickson AW; Habbous S; Hoey C; Jerzak KJ; Das S
NPJ Breast Cancer; 2021 Feb; 7(1):17. PubMed ID: 33602948
[TBL] [Abstract][Full Text] [Related]
39. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.
Cicenas J; Urban P; Küng W; Vuaroqueaux V; Labuhn M; Wight E; Eppenberger U; Eppenberger-Castori S
Eur J Cancer; 2006 Mar; 42(5):636-45. PubMed ID: 16414259
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of c-erbB2 expression in breast cancer.
Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
J Surg Oncol; 2002 Apr; 79(4):216-23. PubMed ID: 11920778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
